Prescient Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Other Revenue	3.59	4.36	3.71	2.43	1.89
Revenue	3.59	4.36	3.71	2.43	1.89
Revenue Growth	-17.60%	17.35%	52.89%	28.52%	59.37%
Gross Profit	3.59	4.36	3.71	2.43	1.89
Selling, General & Admin	4.66	4.83	3.71	3.2	2.82
Research & Development	5.28	6.72	6.97	6.22	3.4
Operating Expenses	10.59	11.89	10.9	9.89	7.1
Operating Income	-7	-7.54	-7.19	-7.46	-5.21
Interest Expense	-0.01	-	-	-	-0.01
Interest & Investment Income	-	0.23	0.69	0.46	0.04
Currency Exchange Gain (Loss)	0.01	-0.01	-0.02	-0.01	0.06
EBT Excluding Unusual Items	-7	-7.32	-6.52	-7	-5.12
Asset Writedown	-	-	-1.72	-	-
Pretax Income	-7	-7.32	-8.24	-7	-5.12
Net Income	-7	-7.32	-8.24	-7	-5.12
Net Income to Common	-7	-7.32	-8.24	-7	-5.12
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	1,030	805	805	728	648
Shares Outstanding (Diluted)	1,030	805	805	728	648
Shares Change	27.88%	-	10.69%	12.31%	5.88%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Free Cash Flow	-7.22	-7.24	-7.4	-6.19	-4.32
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-195.05%	-172.98%	-193.58%	-307.14%	-275.75%
Profit Margin	-195.08%	-168.09%	-221.91%	-288.47%	-270.85%
Free Cash Flow Margin	-201.25%	-166.27%	-199.28%	-254.97%	-228.50%
EBITDA	-6.89	-7.54	-7.19	-7.46	-5.21
EBITDA Margin	-191.97%	-172.97%	-193.56%	-	-275.68%
D&A For EBITDA	0.11	0	0	0	0
EBIT	-7	-7.54	-7.19	-7.46	-5.21
EBIT Margin	-195.05%	-172.98%	-193.58%	-	-275.75%